Skip to main content
Search

Antibody drug conjugates (ADCs)

This learning journey provides an introduction to ADCs, focusing on their mechanism, design, synthesis, and pharmacokinetics. It also explores associated safety and regulatory considerations.

Table of Contents

  1. What is an ADC?
  2. The modality and heterogeneity of ADCs and the opportunities they present
  3. ADC design and technology
  4. Important considerations in ADC design
  5. ADC composition, metabolism and optimisation
  6. ADC synthesis and stability
  7. ADC pharmacokinetics
  8. ADC safety and regulatory considerations
  9. Example of an ADC targeting HER2

1. What is an ADC?

By Dr. Veysel Kayser – The University of Sydney, Australia

An excerpt from Developing therapeutic monoclonal antibodies (mAbs) and antibody-based products 1

  • Play What is an ADC?

2. The modality and heterogeneity of ADCs and the opportunities they present

By Dr. Dhaval K. Shah – University at Buffalo, USA

An excerpt from Modeling of antibody-drug conjugate pharmacokinetics

  • Play The modality and heterogeneity of ADCs and the opportunities they present

3. ADC design and technology

By Prof. L. Nathan Tumey – Binghamton University, USA

An excerpt from Current challenges in the design of antibody-drug conjugates

  • Play ADC design and technology

4. Important considerations in ADC design

By Prof. Nishitha M. Reddy – Vanderbilt University Medical Center, USA

An excerpt from Novel treatment options in lymphoma and leukemia 1

  • Play Important considerations in ADC design

5. ADC composition, metabolism and optimisation

By Dr. Hans-Georg Lerchen – Bayer AG, Germany

An excerpt from Development of antibody prodrug conjugates activated by legumain

  • Play ADC composition, metabolism and optimisation

6. ADC synthesis and stability

By Dr. Hans-Georg Lerchen – Bayer AG, Germany

An excerpt from Development of antibody prodrug conjugates activated by legumain

  • Play ADC synthesis and stability

7. ADC pharmacokinetics

By Dr. Dhaval K. Shah – University at Buffalo, USA

An excerpt from Modeling of antibody-drug conjugate pharmacokinetics

  • Play ADC pharmacokinetics

8. ADC safety and regulatory considerations

By Dr. Krishna Allamneni – Concarlo Therapeutics, USA

An excerpt from Toxicity testing of oncology drugs: unraveling the last 15 years of progress

  • Play ADC safety and regulatory considerations

9. Example of an ADC targeting HER2

By Prof. Michael Wendt – Purdue University, USA

An excerpt from Receptor tyrosine kinase signaling and targeted therapies

  • Play Example of an ADC targeting HER2